Call
+918447748545

Published on: Apr 06, 2020
2 minute read
By: Dr Rajan Choudhary

MicroRNA That Makes Them Fight COVID Better ?

Recently you may have read a New Delhi based International Center for Genetic Engineering and Biotechnology (ICGEB) sequenced the genome (genetic data) of SARS-COV-2 (coronavirus) from India, Italy, US, Nepal and Wuhan, China. They found that the Indian variant of SARS-CoV2 has the potential to be targeted by antiviral RNA within host cells, a feature that is unique to the Indian strain.

This amazing finding has been published on blogs, newspapers and other media as proof that Indians may not suffer as much as the rest of the world when the COVID-19 pandemic hits the country. One headline touted “MicroRNA in Indians may reduce severity of corona attack”, stating “Indians have comparatively better immunity compared to other countries”. Of course this article is being forwarded on WhatsApp, and enough people may take it as gospel. Is it true?

No.

If you want to know why, just look on the Journal’s website:

“these are preliminary reports that have not been peer-reviewed. They should NOT be regarded as conclusive, guide clinical practice/health-related behaviour, or be reported in news media as established information.”

Research is not easy. I could write a very long explanation for why, but I have summarised it below.

SUMMARY:

- To prove x causes y up to a high scientific standard is incredibly difficult

- Even if you think x causes y, someone might find a flaw in your study

- Numbers can be manipulated by statistics to show what you want to believe

- Reporters might not understand the study and mis-report it

- We all want to believe there is a magic cure that will protect us, that makes us special, immune to this disaster so we can get on with our lives. Unfortunately there simply isn’t one. And believing in them without fact checking can cause more harm than good.

IMMUNITY AGAINST COVID

So what about this study? Firstly it is looking at one tiny mechanism in a cell, when a cell can have millions of proteins responsible for a billion different functions in just the cell itself. Secondly it is not peer reviewed. This means no one has fact checked the study to check whether the design is valid, whether the statistics hold up, whether they have missed something or are making incorrect conclusions based off their data. Peer-reviewing a recent paper showing SARS-CoV-2 and HIV were extremely similar disproved this paper as false.

In the authors defence he acknowledges this:

“In our study, which is a purely computational one, we predicted that this microRNA binds to the SARS-Cov2 genome submitted from India. However, it is too early to comment on it because there is only one high coverage sequence from India, so far,”

Thirdly, the news article says that Indians have better immunity because of this “microRNA”. This is wrong. The study sequenced the genome of the virus, not of the Indian population. Antiviral microRNA is found in all people. The study simply suggests that this might be more effective at targeting the Indian strain of COVID, but it does not make any concrete claims that Indians are protected from COVID.

Again, the journal even states this:

“These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information.”

But most importantly, even if the paper suggests that the Indian strain may be less potent, it does not give us an excuse to be reckless. We have to adhere to social distancing, hygiene, lockdown principles in order to prevent infection. Because what happens if you take the article stating “Indians have comparatively better immunity compared to other countries” as fact, use this as an excuse to go about your regular daily lives, and it actually turns out that the microRNA has little to no effect on COVID. This endangers yourself and those around you.

Be sensible. Listen to public health officials.

Dr Rajan Choudhary, UK, Chief Product Officer, Second Medic Inc

www.secondmedic.com

Read Blog

Telemedicine Platform Comparison India: Evaluating the Best Digital Healthcare Providers

Telemedicine has transformed the healthcare landscape in India by making medical services more accessible, affordable, and patient-friendly. With growing smartphone usage, improved internet penetration, and digital health adoption under the Ayushman Bharat Digital Mission (ABDM), teleconsultation platforms have become a primary mode of healthcare for millions. But with multiple platforms available, choosing the right one requires a proper telemedicine platform comparison India.

This blog provides a detailed comparison of India’s leading telemedicine providers and evaluates what sets SecondMedic apart in terms of accessibility, specialist availability, user experience, and overall digital healthcare value.

Why Telemedicine Is Growing Rapidly in India

The demand for digital healthcare platforms is driven by:

Busy lifestyles limiting hospital visits
Rising chronic diseases needing follow-ups
Rural populations needing specialist access
Post-pandemic digital health acceptance
Cost efficiency
Faster access to care

According to Statista, the telemedicine market size in India is increasing significantly, driven by digital transformation and patient willingness to adopt virtual care.

Key Parameters for Comparing Telemedicine Platforms

When comparing telemedicine platforms, users should evaluate the following:

1. Doctor Availability

The range of specialists available-cardiology, dermatology, pediatrics, gynecology, orthopedics, etc.-is crucial.

2. Pricing and Consultation Fees

Costs vary significantly between platforms. Affordable, transparent pricing determines long-term usability.

3. User Interface (UI/UX)

The platform must be easy to navigate, especially for elderly patients.

4. Appointment Wait Time

Faster access to doctors enhances the value of telemedicine.

5. E-Prescriptions

Availability of legal, digital prescriptions is essential for seamless continuity of care.

6. Electronic Health Records (EHR)

Platforms offering unified records improve patient experience.

7. Service Range

A good telemedicine platform should provide:

Teleconsultations
Second opinions
Remote monitoring
Home diagnostics
Preventive health packages

SecondMedic is one of the few platforms offering this full ecosystem.

Comparison of Major Telemedicine Platforms in India

1. SecondMedic

Specialties: Full range including cardiology, dermatology, neurology
Strengths:

Instant teleconsultation
Online specialist access
Remote monitoring tools
Second opinion services
Preventive health packages
Strong chronic care management
Patient-first experience
Easy EHR access
Best For: Those wanting comprehensive digital healthcare

2. Practo

Strengths:

Wide doctor network
Pharmacy integration
Lab test bookings
Limitations:
Higher consultation fees
Variable doctor response times

3. Apollo 24/7

Strengths:

Strong specialist network
Integration with Apollo hospitals
Limitations:
High cost
Limited remote monitoring features

4. Tata 1mg

Strengths:

Affordable consultations
Pharmacy + lab tests
Limitations:
Limited specialist variety
Heavy focus on diagnostics and medicines rather than telemedicine

5. MFine

Strengths:

Good specialist availability
Partner-hospital model
Limitations:
Service coverage varies
Less personalized care

This comparison shows that while multiple telemedicine platforms serve specific needs, SecondMedic provides a more integrated healthcare experience connecting consultations, preventive care, and chronic disease management.

What Makes SecondMedic Stand Out

1. Comprehensive Specialty Coverage

From general physicians to cardiologists, dermatologists, neurologists, endocrinologists, and pediatricians, SecondMedic covers major medical specialties.

2. Strong Chronic Disease Management

Continuous monitoring and scheduled check-ins help manage long-term conditions effectively.

3. Online Second Opinions

Patients needing specialist reassessment benefit from high-quality second opinions from top doctors.

4. Remote Monitoring Ecosystem

Compatible with digital ECGs, glucometers, BP monitors, and other wearable tools.

5. Affordable and Transparent Pricing

SecondMedic offers cost-effective consultations without hidden charges.

6. Easy-to-Use Interface

Designed for all age groups with minimal complexity.

7. Integration with Preventive Health Packages

Users can also book diagnostics, screenings, and wellness plans.

Importance of EHR in Telemedicine Platform Comparison India

Electronic Health Records improve:

Safety
Accuracy
Convenience
Treatment continuity

SecondMedic’s EHR system is aligned with ABDM guidelines, making health data secure and portable.

User Experience and Accessibility

A good telemedicine platform must offer:

Multilingual support
Low-bandwidth compatibility
Easy appointment scheduling
Quick report upload

SecondMedic excels in offering a smooth, user-friendly experience.

Future of Telemedicine Platforms in India

The next evolution includes:

AI-assisted triage
Wearable tech integration
Predictive health alerts
Virtual healthcare kiosks
Full ABDM interoperability

SecondMedic is aligning with these innovations to build the next-generation digital healthcare ecosystem.

Conclusion

Telemedicine platform comparison India reveals that while several platforms offer strong digital health services, SecondMedic stands out due to its integrated care model, specialist availability, chronic disease support, remote monitoring tools, and preventive healthcare programs. For patients seeking a complete, reliable, and patient-centric telemedicine experience, SecondMedic remains a top choice.

To explore telemedicine services, visit www.secondmedic.com

References

NITI Aayog - Telemedicine guidelines for India
Statista - Telemedicine adoption and market size
ABDM - Digital health mission framework
WHO - Teleconsultation standards
IMARC - Digital health ecosystem growth
SecondMedic platform insights

Request A Callback

+91

By using this website/app, I confirm that I am at least 18 years old and consent to the processing of my personal data in accordance with the Terms of Service, Privacy Policy, and Declaration.